Hauge Siri H, Dudman Susanne, Borgen Katrine, Lackenby Angie, Hungnes Olav
Norwegian Institute of Public Health, Oslo, Norway.
Emerg Infect Dis. 2009 Feb;15(2):155-62. doi: 10.3201/eid1502.081031.
In Norway in January 2008, unprecedented levels of oseltamivir resistance were found in 12 of 16 influenza viruses A (H1N1) tested. To investigate the epidemiologic and clinical characteristics of these viruses, we used sequence analysis to test all available subtype H1N1 viruses from the 2007-08 season for resistance. Questionnaires from physicians provided information on predisposing diseases, oseltamivir use, symptoms, and complications. Clinical data were obtained for 265 patients. In total, 183 (67.3%) of 272 viruses were oseltamivir resistant. Resistance was not associated with prior use of antiviral drugs. Symptoms and hospitalization rates did not differ for patients infected with a resistant or a susceptible virus. Oseltamivir-resistant influenza viruses A (H1N1) did not show diminished capability to spread in the absence of selective pressure. The ability of these viruses to sustain their fitness and spread among persons should be considered when shaping future strategies for treating and preventing seasonal and pandemic influenza.
2008年1月在挪威,检测的16株甲型H1N1流感病毒中有12株出现了前所未有的奥司他韦耐药水平。为了调查这些病毒的流行病学和临床特征,我们使用序列分析方法对2007 - 2008年季节所有可用的H1N1亚型病毒进行耐药性检测。医生提供的调查问卷包含了易患疾病、奥司他韦使用情况、症状和并发症等信息。获取了265名患者的临床数据。在总共272株病毒中,有183株(67.3%)对奥司他韦耐药。耐药性与之前使用抗病毒药物无关。感染耐药或敏感病毒的患者症状和住院率没有差异。在没有选择压力的情况下,奥司他韦耐药的甲型H1N1流感病毒传播能力并未减弱。在制定未来季节性和大流行性流感的治疗和预防策略时,应考虑这些病毒维持其适应性并在人群中传播的能力。